View Older Stories View More Recent Stories

Apr 8, 2022 06:30AM Emergent BioSolutions to Release First Quarter 2022 Financial Results and Conduct Conference Call on April 28, 2022
Apr 8, 2022 06:30AM Emergent BioSolutions to Release First Quarter 2022 Financial Results and Conduct Conference Call on April 28, 2022
Mar 23, 2022 04:05PM Emergent BioSolutions Provides Corporate Governance Update
Mar 23, 2022 04:05PM Emergent BioSolutions Provides Corporate Governance Update
Mar 14, 2022 04:05PM Emergent BioSolutions to Participate in Investor Conferences
Mar 14, 2022 04:05PM Emergent BioSolutions to Participate in Investor Conferences
Mar 11, 2022 06:34AM Emergent BioSolutions Initiates Phase 1 Study Evaluating Potential Intranasal Treatment for Cyanide Poisoning
Mar 11, 2022 06:34AM Emergent BioSolutions Initiates Phase 1 Study Evaluating Potential Intranasal Treatment for Cyanide Poisoning
Feb 24, 2022 04:05PM Emergent BioSolutions Reports Financial Results for Fourth Quarter 2021
Feb 7, 2022 06:30AM Emergent BioSolutions to Release Fourth Quarter 2021 Financial Results and Conduct Conference Call on February 24, 2022
Feb 7, 2022 06:30AM Emergent BioSolutions to Release Fourth Quarter 2021 Financial Results and Conduct Conference Call on February 24, 2022
Jan 14, 2022 06:31AM Emergent BioSolutions (EBS) Announces Retirement of Founder and Executive Chairman
Jan 14, 2022 06:30AM Founder and Executive Chairman of Emergent BioSolutions Announces Retirement
Jan 14, 2022 06:30AM Founder and Executive Chairman of Emergent BioSolutions Announces Retirement
Jan 10, 2022 05:52AM Emergent BioSolutions (EBS) Issues 2022 Guidance; Reports Prelim FY21 Results
Jan 9, 2022 02:00PM Emergent BioSolutions Announces 2022 Financial Guidance, Provides Preliminary 2021 Results
Jan 9, 2022 02:00PM Emergent BioSolutions Announces 2022 Financial Guidance, Provides Preliminary 2021 Results
Jan 3, 2022 06:30AM Emergent BioSolutions to Participate in Investor Conferences
Jan 3, 2022 06:30AM Emergent BioSolutions to Participate in Investor Conferences
Dec 16, 2021 07:30AM Emergent BioSolutions Announces Initiation of Phase 1 Study Evaluating Its Universal Influenza Vaccine Candidate
Dec 16, 2021 07:30AM Emergent BioSolutions Announces Initiation of Phase 1 Study Evaluating Its Universal Influenza Vaccine Candidate
Nov 11, 2021 04:08PM Emergent BioSolutions (EBS) Announces $250M Stock Repurchase Program
Nov 11, 2021 04:05PM Emergent BioSolutions Announces Stock Repurchase Program
Nov 11, 2021 04:05PM Emergent BioSolutions Announces Stock Repurchase Program
Nov 4, 2021 04:05PM Emergent BioSolutions Reports Financial Results For Third Quarter 2021
Nov 4, 2021 04:05PM Emergent BioSolutions Reports Financial Results For Third Quarter 2021
Oct 18, 2021 06:30AM Emergent BioSolutions to Release Third Quarter 2021 Financial Results and Conduct a Conference Call on November 4, 2021
Oct 18, 2021 06:30AM Emergent BioSolutions to Release Third Quarter 2021 Financial Results and Conduct a Conference Call on November 4, 2021
Oct 15, 2021 06:30AM Emergent BioSolutions (EBS) Initiates Pivotal Phase 3 Trial of Its Single-Dose Chikungunya Vaccine Candidate, CHIKV VLP
Oct 15, 2021 06:30AM Emergent BioSolutions Announces Initiation of Pivotal Phase 3 Study Evaluating the Safety and Immunogenicity of Its Single-Dose Chikungunya Vaccine Candidate, CHIKV VLP
Oct 15, 2021 06:30AM Emergent BioSolutions Announces Initiation of Pivotal Phase 3 Study Evaluating the Safety and Immunogenicity of Its Single-Dose Chikungunya Vaccine Candidate, CHIKV VLP
Sep 14, 2021 08:01AM Emergent BioSolutions (EBS) Secures Multi-Year Development and Manufacturing Agreement with Providence Therapeutics for its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B
Sep 14, 2021 08:00AM Emergent BioSolutions Secures Multi-Year Development and Manufacturing Agreement with Providence Therapeutics for its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B
Sep 14, 2021 08:00AM Emergent BioSolutions Secures Multi-Year Development and Manufacturing Agreement with Providence Therapeutics for its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B
Aug 25, 2021 06:31AM Emergent's (EBS) COVID-19 Human Immune Globulin Product Candidate to be Evaluated in NIH-Sponsored Phase 3 Clinical Trial of Hyperimmune Intravenous Immunoglobulin for Outpatient Treatment of COVID-19
Aug 25, 2021 06:30AM Emergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Evaluated in NIH-Sponsored Phase 3 Clinical Trial (INSIGHT-012) of Hyperimmune Intravenous Immunoglobulin for Outpatient
Aug 25, 2021 06:30AM Emergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Evaluated in NIH-Sponsored Phase 3 Clinical Trial (INSIGHT-012) of Hyperimmune Intravenous Immunoglobulin for Outpatient
Aug 23, 2021 04:05PM Emergent BioSolutions to Participate in Investor Conferences
Aug 23, 2021 04:05PM Emergent BioSolutions to Participate in Investor Conferences
Jul 29, 2021 04:05PM Emergent BioSolutions Reports Financial Results For Second Quarter 2021
Jul 29, 2021 04:05PM Emergent BioSolutions Reports Financial Results For Second Quarter 2021
Jul 29, 2021 07:48AM Emergent BioSolutions (EBS) to Resume Manufacturing Covid-19 Vaccine at Bayview Facility
Jul 29, 2021 07:24AM Emergent BioSolutions to Resume Manufacturing Covid-19 Vaccine at Bayview Facility
Jul 29, 2021 07:24AM Emergent BioSolutions to Resume Manufacturing Covid-19 Vaccine at Bayview Facility
Jul 26, 2021 09:01AM Reverse the Silence Campaign Casts a National Spotlight on Overdose Risks Associated with Opioid Use
Jul 26, 2021 09:01AM Reverse the Silence Campaign Casts a National Spotlight on Overdose Risks Associated with Opioid Use
Jul 15, 2021 06:30AM Emergent BioSolutions to Release Second Quarter 2021 Financial Results and Conduct a Conference Call on July 29, 2021
Jul 15, 2021 06:30AM Emergent BioSolutions to Release Second Quarter 2021 Financial Results and Conduct a Conference Call on July 29, 2021
Jun 11, 2021 04:35PM COVID-19 Vaccine Drug Substance Manufactured by Emergent BioSolutions Authorized as Part of Johnson & Johnson’s Emergency Use Authorization
Jun 11, 2021 04:35PM COVID-19 Vaccine Drug Substance Manufactured by Emergent BioSolutions Authorized as Part of Johnson & Johnson’s Emergency Use Authorization
View More Recent Stories View Older Stories